Trial Profile
A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAMUSCULAR PERAMIVIR IN SUBJECTS WITH UNCOMPLICATED ACUTE INFLUENZA
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Peramivir (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors BioCryst Pharmaceuticals
- 30 Jul 2022 This trial has been completed in France, according to European Clinical Trials Database record (23 Jan 2008).
- 30 Jul 2022 This trial has been completed in Spain, according to European Clinical Trials Database record (23 Jan 2008).
- 03 Jul 2012 Planned number of patients 750 added as reported by European Clinical Trials Database record.